Searchable abstracts of presentations at key conferences in endocrinology

ea0008ds1 | Lectures | SFE2004

Can we resurrect beta cell function? Insights from GLP-1

Matthews DR

The incretin access is the descriptive term behind the observed phenomenon that one can elicit more insulin secretion from oral glucose than from an equivalent intravenous stimulus. The major causes of this are two gut hormones GIP and GLP-1.GLP-1 is secreted in the intestine by the L cells and has effects at the beta cell, in the brain, and on gastric motility. At the beta cell it binds onto G protein receptors which activate the metabolic pathways rela...

ea0095oc5.7 | Oral Communications 5 | BSPED2023

Breast milk-induced hypercalcaemia – a retrospective study to describe biochemical and radiological outcomes if no intervention is offered

Sandhya Govindarajan Dr. , Amish Chinoy Dr. , Imran Zamir Dr. , Raja Padidela Dr. , Zulf Mughal Dr.

Introduction: Asymptomatic hypercalcaemia in infants who are exclusively breast-fed is recognised in clinical practice but has never been evaluated and outcomes described if breast feeding is continued.Objective: We conducted a novel retrospective analysis to evaluate the biochemical and radiological outcomes of breast milk-induced hypercalcaemia. Methods: A multi-site retrospectiv...

ea0096p14 | Section | UKINETS2023

Pituitary disease in MEN1: follow up of patients in Northern Ireland

Muhammad Aamir Shahzad Dr , Ahmed Dr. Doua , D'Arcy Dr. Robert , Graham Dr. Una , McHenry Dr. Claire

Multiple Endocrine Neoplasia type 1 (MEN1) is a rare hereditary autosomal dominant disorder characterised by the occurrence of multiple endocrine tumours, predominantly affecting parathyroid glands, pancreatic islet cells and anterior pituitary. Consensus guidelines for MEN1 recommend intensive clinical, biochemical and radiological surveillance commencing in early childhood. The current regimen, which is subject to debate given lack of strong evidence for some aspects of care...

ea0096p20 | Section | UKINETS2023

Carcinoid heart disease in patients unfit for surgery: a case series of medically managed patients

Nosheen Sattar Dr , Nwabunike Dr. Chidinma , Munir Dr. Alia

Background: Carcinoid Heart Disease (CHD) is a well-documented but devastating complication of metastatic neuroendocrine tumours (mNETs). Occurring in approximately 20% of patients with Carcinoid Syndrome (CS) the prognosis is poor, with a 3-year survival of 31% versus 68% in patients with mNETs without CHD1. Management of these patients requires a multidisciplinary approach to manage tumour load via medical and/or surgical options, alongside contro...

ea0055wc4 | Workshop C: Disorders of the thyroid gland (I) | SFEEU2018

A common case of goitre, thyroid nodules and thyroid carcinoma

Tansey Dr David J , Gibney Dr James

A 31 year-old woman is referred into the Endocrine clinic with a palpable mass in her right anterior neck that was found incidentally by her GP. She had no known past medical history, did not take any medications and had not noticed any dysphagia, neck pain, or compressive symptoms. On clinical exam, there was an enlarged thyroid with a 1.5-cm left-sided thyroid nodule that moved on swallowing. There was no palpable cervical lymphadenopathy. TSH was 2.5 mIU/l (0.29–5.1 mI...

ea0096p8 | Section | UKINETS2023

Audit of glycaemic control and assessment in Pancreatic Neuroendocrine Tumours (pNETS) in Sheffield NET Centre ENETS Centre of Excellence

Pieri Dr. Beatrice , Munir Dr. Alia

Background: There may be a bidirectional association between glycaemia and pNETS. Pre-existing diabetes mellitus(DM) is a recognised risk factor for the development of pNETS. Prevalence of DM in pNETS has been reported as 12-26% depending on patient age and tumour location. DM due to pNETS is classified as type 3C pancreatogenic diabetes, Type 3D caused by hormone disorders or Type 3E induced by medications. Functional pNETS, medical therapies and pancreatic s...

ea0094cc3 | Section | SFEBES2023

“A case of metastatic insulinoma: a real challenge to manage”

Tahir Chohan Dr Muhammad , Atherton Dr Philip , Margetts Dr Jane , Littler Dr Peter , Pandanaboyana Mr Sanjay , Joshi Dr Ashwin , Bishop Dr David , Carey Dr Peter , Artham Dr Satish , Nayar Dr Rahul , Mitchell Dr Anna L , Gan Dr Earn H

Background: Insulinomas are the commonest functional neuroendocrine tumours (NETs) but metastatic insulinomas are rare (incidence <2%) and their management can be challenging. We report a case of metastatic insulinoma requiring multiple treatment modalities to achieve biochemical control.Case Presentation: A 77 year old healthy female was admitted with severe spontaneous hypoglycaemia (glucose 1.8mmol/l) due to endog...

ea0063pl1 | Designing Cities and Homes as Exercise Machines: Helping endocrinologists to fight metabolic disease | ECE2019

Designing Cities and Homes as Exercise Machines: Helping endocrinologists to fight metabolic disease

Friedman Dr Avi

The obesity epidemic has affected many nations. In Canada, by some estimates, more than 6 million Canadian adults age 20 to 64 are overweight and nearly 3 million are obese. The common tendency is to blame people’s dietary choices and sedentary habits. Yet, it can also be argued that poor urban planning practices have largely contributed to a lack of active lifestyles. Low-density suburban sprawl, long commutes, diminishing land for green area and the elimination of sidew...

ea0063pl5 | Paracrine regulation of the adrenal cortex | ECE2019

Paracrine regulation of the adrenal cortex

Lefebvre Dr Herve

Numerous <i>in vitro</i>studies have shown that the secretory activity of the human adrenal cortex is activated by a wide variety of neuropeptides and conventional neurotransmitters released in the vicinity of adrenocortical cells by chromaffin cells, endothelial cells, adipocytes, cells of the immune system and nerve endings. The role of these paracrine factors in the physiological control of the adrenocortical function remains unclear, especially for cortisol...

ea0063s24.2 | What's new in the Adrenal Cortex? (Endorsed by the European Journal of Endocrinology) | ECE2019

Primary hyperaldosteronism: does our treatment work?

Williams Dr Tracy Ann

Primary aldosteronism (PA) has a prevalence of 5–15% in the general population with hypertension and patients with PA display an increased frequency of target organ damage and cardiovascular damage than patients with hypertension with matched cardiovascular risk profiles. The unilateral and bilateral forms of PA are treated differently usually surgically (unilateral PA) or by antagonism of the receptor for aldosterone (bilateral PA). Medically-treated patients with PA hav...